Literature DB >> 3285212

Loss of ras oncogene mutation in a myelodysplastic syndrome after low-dose cytarabine therapy.

D M Layton, G J Mufti, J Lyons, J W Janssen, C R Bartram.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3285212     DOI： 10.1056/NEJM198806023182215

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Oncogene expression in primary myelodysplasia: correlation with haematological, karyotypic, and clinical progression.

Authors:  R M Hutchinson; J H Pringle; S C Knight; I Lauder; A Potter; C Jagger
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

Review 2.  The polymerase chain reaction: an improved method for the analysis of nucleic acids.

Authors:  H P Vosberg
Journal:  Hum Genet       Date:  1989-08       Impact factor: 4.132

Review 3.  Progress in the therapy of myelodysplastic syndromes.

Authors:  M A Boogaerts
Journal:  Blut       Date:  1989-06

4.  Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Authors:  H H Gerhartz; R Marcus; A Delmer; H Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; P Sonneveld; B Labar
Journal:  Infection       Date:  1992       Impact factor: 3.553

5.  Observations on the transcriptional activity of the glutathione S-transferase pi gene in human haematological malignancies and in the peripheral leucocytes of cancer patients under chemotherapy.

Authors:  S McQuaid; S McCann; P Daly; E Lawlor; P Humphries
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.